- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
- Ascentage Pharma Announces 2023 Annual Results
- AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting
- Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
More ▼
Key statistics
On Monday, Ascentage Pharma Group International (6855:HKG) closed at 18.72, 21.40% above the 52 week low of 15.42 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.22 |
---|---|
High | 18.88 |
Low | 18.22 |
Bid | 18.70 |
Offer | 18.72 |
Previous close | 18.40 |
Average volume | 842.94k |
---|---|
Shares outstanding | 290.21m |
Free float | 212.89m |
P/E (TTM) | -- |
Market cap | 5.34bn HKD |
EPS (TTM) | -3.53 HKD |
Data delayed at least 15 minutes, as of May 06 2024 09:08 BST.
More ▼